iptacopan (Fabhalta®)

Status: Excluded due to NICE appraisal
Product meets AWMSG exclusion criteria due to NICE appraisals TA1102: Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)
Medicine details
Medicine name	iptacopan (Fabhalta®)
Formulation	200 mg hard capsules
Reference number	5123
Indication	Treatment of adult patients with complement 3 glomerulopathy (C3G) in combination with a renin-angiotensin system (RAS) inhibitor, or in patients who are RAS-inhibitor intolerant, or for whom a RAS inhibitor is contraindicated
Company	Novartis Pharmaceuticals UK Ltd
BNF chapter	Malignant disease & immunosuppression
Assessment type	N/A
Status	Excluded due to NICE appraisal
Advice number	TA1102
Date of issue	31/10/2025
NICE guidance	TA1102: Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)